Friedreich's ataxia (FRDA) is a neurodegenerative disease caused by inherited deficiency of the mitochondrial protein Frataxin (FXN), which has no approved therapy and is an area in which biomarkers are needed for clinical development. Here, we investigated the consequences of FXN deficiency in patient-derived FRDA fibroblast cell models, the FRDA mouse model KIKO, and in whole blood collected from patients with FRDA. We observed decreased mitochondrial copy number in all the three FRDA models tested: cells, mice and patient blood. In addition, we observed 40% residual mitochondrial gene expression in FRDA patient blood. These deficiencies of mitochondrial biogenesis in FRDA cells and patient blood are significantly correlated with FXN expression, consistent with the idea that the decreased mitochondrial biogenesis is a consequence of FXN deficiency. The observations appear relevant to the FRDA pathophysiological mechanism, as FXN-dependent deficiency in mitochondrial biogenesis and consequent mitochondrial bioenergetic defect could contribute to the neurodegenerative process. The observations may also have translational potential, as mitochondrial biogenesis could now be followed as a clinical biomarker of FRDA as a correlate of disease severity, progression, and therapeutic effect. Also, mitochondrial copy number in blood is objective, scalar and more investigator-independent than clinical-neurological patient rating scales. Thus, FXN deficiency causes mitochondrial deficiency in FRDA cells, the KIKO mouse model, and in whole blood of patients with FRDA, and this deficiency could potentially be used in clinical trial design.
Introduction
Frataxin (FXN) is a nuclear-encoded mitochondrial protein whose function in mitochondria supports the formation of iron-sulfur clusters, protection from oxidative stress, and maintenance of iron homeostasis (1, 2) . Decreased FXN expression as a result of expanded GAA repeats, in the first intron of FXN gene, leads to a progressive, neuro-muscular disease called Friedreich's ataxia (FRDA) (3) . It is characterized by impaired proprioception, muscle weakness, hypertrophic cardiomyopathy and diabetes (4) . FRDA is most common autosomal recessive disorder affecting 1 in 20,000 Caucasians (5) . Currently, there is no cure or effective treatment for this devastating disease (6) .
Decreased FXN in FRDA increases mitochondrial and nuclear DNA damage in yeast, mice and humans (7) (8) (9) (10) . FXN deficiency also results in enhanced oxidative stress and diminished mitochondrial function (2, 11) . Despite of evidence, that decrease in FXN is associated with enhanced mitochondrial DNA damage and diminished mitochondrial function in FRDA, effect of FXN deficiency on overall mitochondrial biogenesis is unclear.
Here, we investigated the effect of decreased FXN on mitochondrial biogenesis in FRDA patient fibroblast cells, KIKO mice and whole blood of patients with FRDA. We observe a significant decrease in mitochondrial copy number in all the three models tested. In addition, FXN knockdown decreases mitochondrial copy number in healthy fibroblast and its overexpression increases mitochondrial protein expression in FRDA patient fibroblast, suggesting FXN-dependent mitochondrial biogenesis defect in FRDA. Further, we observe significant positive correlation between FXN mRNA expression to mitochondrial copy number in FRDA fibroblasts and whole blood. There is also decrease in mitochondrial subunit gene expression in FRDA whole blood. The measurement of mitochondrial copy number in blood is objective, rapid and appears to relate to FXN expression, which relates to disease severity, age of onset, and progression. Thus, we show that mitochondrial copy number could potentially be used as a biomarker for determining disease severity and in support of effective therapeutic evaluation.
Results
There is a decrease in mitochondrial mass in FRDA fibroblasts FXN functions in mitochondrial iron-sulfur cluster biogenesis. Iron-sulfur clusters are required in mitochondrial enzyme complexes I, II and III and other mitochondrial enzymes (1) . Therefore, a decrease in FXN might impact mitochondrial function and number. Healthy and FRDA fibroblast derived from patients were quantified for mitochondrial mass by staining with MitoTrackerV R Deep Red FM, which stains active mitochondria and is retained after fixation. Its intensity per cell was measured with MetaXpressV R image acquisition and analysis software. FRDA fibroblasts, GM4078 had 68% (P < 0.017, n ¼ 8) and a 52% (P < 1.6Â10 À4 , n ¼ 8) residual mitochondrial mass compared to healthy fibroblasts, GM-3440 and GM-8402, respectively (Fig. 1) . Similarly, FRDA fibroblast GM3816 had 51% (P < 2Â10
À4
, n ¼ 8) and 38% (P < 3.5Â10
À6
, n ¼ 8) residual mitochondrial mass compared to GM-3440 and GM-8402, respectively (Fig. 1) . Thus, we observe a significant decrease in mitochondrial mass in FRDA fibroblasts compared to healthy fibroblasts.
FXN expression correlates with mitochondrial biogenesis in fibroblast cells
To investigate the relationship of FXN to mitochondrial biogenesis, we measured mitochondrial copy number as ratio of mitochondrial DNA over nuclear DNA (mt/nDNA) by quantitative PCR (qPCR). In addition, the relationship of mitochondrial biogenesis replication factors-Transcription Factor A-Mitochondrial (TFAM) and Nuclear Respiratory Factory 1 (NRF1) to FXN level was quantified, by qRT-PCR and linear regressions was carried out (Fig. 2) . A significant and strong positive correlation is observed between FXN mRNA expression and mitochondrial biogenesis markers-mt/nDNA, TFAM and NRF1, with r 2 correlation coefficients of 0.816 (P < 0.0001), 0.722 (P < 0.0001) and 0.815 (P < 0.0005), respectively. This clearly indicates that FXN expression is significantly and positively correlated with mitochondrial biogenesis in fibroblast cells.
FXN knockdown in healthy fibroblasts decreases their mitochondrial copy number
To further understand FXN-dependent effect of mitochondrial biogenesis, FXN expression was knocked down using FXN siRNA (siFXN) in two different healthy fibroblasts GM-3440 and GM-8402. Scrambled siRNA (siCTL) was used as a control to determine any non-specific target effect of RNAi knockdown. As expected, we see no significant difference in FXN expression and mitochondrial copy number when comparing siCTL-treated cells to untreated healthy fibroblast, confirming absence of any non-specific targeting effect of RNAi knockdown (data not shown). siFXN treatment significantly decreased FXN expression with residual FXN of 3% (P < 3.6Â10 À4 , n ¼ 3) in both GM3440 and GM8402 (Fig. 3A) . There was also decrease in mt/ nDNA ratio with residual mitochondrial copy number of 35% (P < 7.4Â10 À4 , n ¼ 3) and 47% (P < 1.9Â10 À4 , n ¼ 3) in GM3440 and GM8402, respectively; 5 days post transfection (Fig. 3A) . Thus, a long-term FXN knockdown significantly decreases mitochondrial biogenesis. We then investigated the effect of FXN knockdown on mt/ nDNA ratio at different time points in GM3440 (Fig. 3B) . We observe that 2 days post-siFXN transfection, although FXN was significantly knocked down with 2% residual FXN (P < 5.8Â10 À5 , n ¼ 3), there was no significant difference in mt/nDNA copy number. After 5 days of siFXN transfection, FXN remains significantly knocked down with 3% residual FXN (P < 3.6Â10
À4
, n ¼ 3) and mt/nDNA copy number significantly decreases with 35% residual mitochondria (P < 7.4Â10
À6
, n ¼ 3). Thus, a prolonged FXN-deficiency appears to be required for a decline in mitochondrial biogenesis. We previously demonstrated that there is a lag of 4.5 days for depletion of FXN protein in mitochondria, after knockdown of FXN transcript in the nucleus (30) . The delay in decline of mitochondrial biogenesis by mtDNA/nDNA ratio observed at 5 days post-siFXN in Figure 3B is likely the result of mitochondrial FXN protein turnover. Also consistent with our hypothesis, at 7 days post-transfection as the siRNA wears off, residual FXN increases by 25% (P < 4.1Â10 À4 , n ¼ 3) and simultaneously residual mt/nDNA copy number also increases by 53% (P < 2.5Â10 À4 , n ¼ 3). Overall, FXN deficiency produces a decline in mitochondrial biogenesis, whereas FXN increase produces a rise in mitochondrial biogenesis.
FXN overexpression in FRDA patient fibroblast increases mitochondrial biogenesis
We also investigated the consequences of FXN overexpression above the low levels observed in FRDA patient fibroblast on mitochondrial biogenesis as visualized by Voltage-Dependent Anion Channel (VDAC) expression, a commonly used marker of mitochondrial biogenesis. Patient fibroblast GM4078 was transfected, with a vector (pcDNA3.1-frataxin-flag) (12) which expressed FXN protein with a C-terminal flag epitope tag. Fibroblast transfected with vector (pcDNA3.1), which did not have any insert, was used as a negative control. The construct (pcDNA3.1-frataxin-flag) drove high FXN expression in fibroblast cell as detected by anti-FLAG antibody (Fig. 4A ). There was increase in FXN expression by 4 fold (P < 8.9Â10 À4 , n ¼ 3) and 5.3 fold (P < 3.2Â10 À4 , n ¼ 3), respectively, 2 days and 4 days posttransfection (Fig. 4B ). VDAC expression increased by 1.5 fold (P < 5.8Â10 À5 , n ¼ 3) and 2.3 fold (P < 4.2Â10
À5
, n ¼ 3) (Fig. 4B) , respectively, 2 days and 4 days post-transfection. This confirms FXN-dependent effect on mitochondrial biogenesis.
Mitochondrial copy defect in brain and muscle of KIKO mouse model of FRDA Since stable and transient FXN deficiency decreased mitochondrial biogenesis in cell models, we investigated mitochondrial biogenesis in the FRDA KIKO mouse model that has a $40% residual FXN level (13) . Brain and skeletal muscle tissues were collected from 10 Knock-in Knock-out (KIKO) mice and 7 agematched wildtype (WT) mice. qPCR was used to analyze mitochondrial DNA copy number as ratio of mt-ND1 (mitochondrial gene) to Cftr (nuclear gene). We observed significant decrease, with 63% (P < 0.004, n ¼ 7) residual mt/nDNA in the brain, and 66% (P < 0.03, n ¼ 7) residual mt/nDNA in skeletal muscle tissue, respectively, compared to wild type mice (Fig. 5) .
Mitochondrial biogenesis is deficient in FRDA patient blood
Given the consistent deficiency in mitochondrial biogenesis in patient cells, FXN knockdown cells and KIKO mouse model, the question arose whether the mitochondrial biogenesis defect could be observed in patient blood, and could be used as a minimally invasive biomarker. We used whole blood from five affected individuals and five age-matched controls to determine the effect of decreased FXN on mitochondrial biogenesis. Consistent with our other results, there was a mitochondrial (A) qPCR analysis of mt/nDNA ratio 5 days post transfection in GM3440 and GM8402. (B) qPCR analysis of mt/nDNA ratio at different time points in GM3440. Bars represent averages 6 standard deviations (n ¼ 3, *P < 0.05, **P < 0.01, ***P < 0.001).
biogenesis defect in FRDA patient blood with 60% residual (P < 3.2Â10 À4 , n ¼ 5) mt/nDNA compared to age matched controls (Fig. 6A ). In addition, there is strong and significant positive correlation of FXN mRNA expression to mitochondrial copy number with correlation coefficient 0.8289 (n ¼ 5, P < 0.0003) (Fig. 6B) . Trends toward deficient mitochondrial complex-I gene expression in FRDA has been shown (14) . We further confirm defective expression of multiple mitochondrial complex subunit genes by measuring expression-mtND6 (complex-I), mtCO2 (complex-II) and mtATP6 (complex-V) in patients with FRDA by using qRT-PCR (Fig. 6C) . We see about 40% (n ¼ 5, P < 0.002), residual mitochondrial gene expression in patients with FRDA compared to healthy controls in 3/3 mitochondrial genes. Thus, there is defective mitochondrial gene expression as well as mitochondrial biogenesis as measured by mt/nDNA ratio in blood of patients with FRDA.
Discussion

FXN-deficiency causes a mitochondrial biogenesis defect
FXN deficiency in FRDA impairs mitochondrial respiratory chain function and enzymes involved in antioxidant defense mechanism (2, 11) . FXN deficiency also increases mitochondrial and nuclear DNA damage in multiple FRDA models (7-10). Although diminished mitochondrial function and enhanced mitochondrial DNA damage have been reported in FRDA, its effect on overall mitochondrial biogenesis is unclear. Decreased expression of PGC1-alpha, a transcriptional regulator of mitochondrial biogenesis, has been reported in FRDA patient fibroblasts (15) . Another study shows increase in PGC1alpha and signals upstream in FRDA patient fibroblast due to ATP deficiency and ROS production. However, its effect on mitochondrial content is not clear (16) .
Here, we clearly show that FXN-deficiency causes a mitochondrial biogenesis defect in multiple situations, including FRDA patient fibroblast cells, healthy fibroblast cells in which FXN has been knocked down, tissues of an FRDA mouse model, and in blood of patients with FRDA ( Figs 1-4,6 ). In addition, we show FXN overexpression in FRDA patient fibroblast cells increases mitochondrial protein expression (Fig. 5) . After the siRNA knockdown 'wears off ' at 7 days, mtDNA/nDNA rises immediately (Fig. 3B) . Also, mitochondrial biogenesis is correlated to FXN expression (Figs 2, 6B ). These observations support the idea that FXN deficiency causes defects in mitochondrial biogenesis, and that FXN rescues mitochondrial biogenesis. This also supports the idea that mitochondrial biogenesis can be measured to estimate some downstream consequence of FXN deficiency, such as disease severity, progression and therapeutic effectiveness.
Potential mechanism for FXN-dependent mitobiogenesis defect
Since we see defective mitochondrial biogenesis in multiple FRDA models, we tested the possibility of FXN knockdown in healthy cells and its effect on mitochondrial biogenesis. As expected, FXN knockdown in healthy human fibroblast showed significant decrease in FXN expression and mitochondrial copy number by 97% and 60%, respectively; 5 days post-siFXN transfection (Fig. 3) However, 2 days post-siFXN transfection; there was no change in mitochondrial copy number despite of significant reduction in FXN expression by 97% (Fig. 3B) . Our previous experiments demonstrate that even after FXN transcript loss in the nucleus, it takes about 4.5 days for FXN protein to decrease in the mitochondria, which was consistent with the time at which mitochondrial biogenesis decreases in FXN knocked down healthy fibroblast (Fig. 3B) .
There could be multiple potential mechanisms that link FXN deficiency to mitochondrial biogenesis defect. Since FXN's functions include the formation of iron-sulfur clusters (17) and muscle tissues of KIKO and WT mice followed by qPCR analysis of mitochondrial DNA copy number over nuclear DNA copy number (mt-ND1/Cftr). Bars represent averages 6 standard deviations (n ¼ 7, *P < 0.05, **P < 0.01, ***P < 0.001).
iron-sulfur clusters are involved in mitochondrial electron transport and antioxidant defense (18) , a defect in mitochondrial iron-sulfur cluster proteins could lead to deficiencies in a critical metabolite required for mitochondrial biogenesis. Defects in such a metabolite could lead to selective mitophagy and reduced mitobiogenesis (19) . Alternatively, multiple DNA replication and repair proteins contain iron-sulfur clusters, and a decrease in expression or activity of such enzymes could inhibit mitochondrial replication and or repair (20, 21) . Thus, better understanding of cellular and molecular events involved in downstream of frataxin's iron-sulfur function and upstream of mitochondrial biogenesis could perhaps identify novel therapeutic targets.
Mitochondrial biogenesis defect and FRDA pathophysiology
Since mitochondrial biogenesis was observed to decrease in multiple tissues of KIKO mice, one question is what consequence this would have for mitochondrial pathophysiology. There has been agreement that decreased mitochondrial function can contribute to multiple neurodegenerative disorders including Huntington's disease, Parkinson's disease, CharcotMarie-Tooth disease and FRDA (22, 23) . In addition, FXN is highly expressed in tissues with high energy demand, including large sensory neurons of dorsal root ganglion, skeletal muscle, heart and pancreas, which are also the major tissues affected in FRDA (24) . A defect in energy generation due to deficient mitochondrial biogenesis (as shown here) appears to drive cellular apoptosis in FRDA (21, 25) and could potentially contribute to the progressive degenerative nature of the disease.
Summary and prospects
Defective mitochondrial biogenesis has been indirectly proposed in FRDA based on diminished iron-sulfur cluster enzyme activity and decrease in mitochondrial DNA in cell circulating free nucleic acid in plasma of human blood (17, (26) (27) (28) . The results presented here clearly shows that FXN deficiency in vitro and in vivo leads to mitochondrial biogenesis defects in cell and animal models of FRDA, and in blood of patients with FRDA. Thus, FXN deficiency causes defects in mitochondrial biogenesis, which could be relevant to understanding the progressive neurodegenerative pathomechanism of FRDA.
Since there is no approved therapy for FRDA and there is a dearth of blood-based biomarkers, deficient mt/nDNA ratio could serve as biomarkers of disease severity, disease progression, and deficient mitochondrial gene expression and therapeutic effect. Thus, a significant positive correlation of FXN expression and deficient mitochondrial biogenesis in patient blood (Fig. 6) suggests the prospect that mitochondrial biogenesis could become a reliable and minimally invasive blood-based biomarker for determining disease progression and finding effective therapy in FRDA. Since we show the mitobiogenesis defect responds to frataxin increase, drugs that increase frataxin would be expected to increase mitochondrial biogenesis in blood of FRDA patients.
Materials and Methods
Cell culture
Human control (GM-8402 and GM-3440) and FRDA patient fibroblasts (GM-3816 and GM-4078) were obtained from the Coriell Institute for Medical Research repository. They were maintained at 37 C in a humidified atmosphere with 5% CO 2 . DMEM (Corning, Inc., Corning, NY, USA) supplemented with 10% fetal bovine serum (JR-Scientific, Woodland, CA, USA), 1x PenicillinStreptomycin Solution (Corning, Inc., Corning, NY, USA) was used as growth media. Media was changed every two days.
Mice model and tissue isolation
10 knock in-knock-out (KIKO) mice (Jackson Laboratories #012329 B6.Cg-Fxn(tm1.1Pand) Fxn(tm1Mkn/J)) and 7 littermate wild type (WT) mice were used for this study. They were 9 months old and individually housed in a vivarium maintained at 22-24 C and 40-60% relative humidity with a 12-h light/12-h dark cycle. The University of California Institutional Animal Care and Use Committee approved all the experimental procedures. The mice were euthanized with brief isoflurane vaporizer followed by cervical dislocation and tissues were immediately removed and stored in RNA later at À20 C until utilized for experiments.
Patient consent and blood collection
The human clinical study was reviewed and approved by the Investigational Review Board of the University of California, Los Angeles. All patients were provided written informed consent . Bars represent averages 6 standard deviations (n ¼ 7, *P < 0.05, **P < 0.01, ***P < 0.001).
prior to initiation of the study. 
Quantitative PCR (qPCR)
cDNA was synthesized from mRNA with iScript cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules, CA, USA) per manufacturer's instruction in a C1000 Touch Thermal Cycler (Bio-Rad Laboratories, Hercules, CA, USA). qPCR was performed using SensiFAST SYBR No-ROX Kit (Bioline, Taunton, MA, USA) in Roche Lightcycler 480 (Roche Diagnostics, Indianapolis, IN, USA). The second derivative of the amplification curve was used to determine the cycle threshold, and the data were analyzed by delta CT calculation. Primer sets used in qPCR are listed in Table 1 . Measuring mitochondrial mass by Hi content screening Images were captured using DAPI filter, Cy5 filter and GFP filter for DAPI, Mitotracker and Alexa Fluor respectively (29) . Mitotracker intensity per cell was measured using MetaXpressV R image acquisition and analysis software.
Protein extraction and western blot
